A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

NCT01923207 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG: DX-2930
DRUG: Placebo

Sponsor

Shire

Collaborators

[object Object]